Literature DB >> 29135069

Impaired secretion of active GLP-1 in patients with hypertriglyceridaemia: A novel lipotoxicity paradigm?

Xiangxiang Wang1,2, Jia Liu1,2, Chaolin Li1,2,3, Meng Zhao1,2, Lu Liu1,2, Qingbo Guan1,2, Haiqing Zhang1,2, Xu Zhang1,2, Ling Gao1,4, Jiajun Zhao1,2, Yongfeng Song1,2.   

Abstract

BACKGROUND: Lipotoxicity plays an important role in the pathogenesis of β-cell dysfunction. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that exerts beneficial effects on the number and function of islet β cells. However, the effect of lipotoxicity on GLP-1 secretion is still unknown.
METHODS: Twenty-five patients who were newly diagnosed with diabetes were recruited from 400 subjects based on 75-g Oral Glucose Tolerance Test. Patients were divided into diabetes (DM) and DM combined with hypertriglyceridaemia (DM + HTG) groups according to their serum triglyceride (TG) levels. Seventy-one normal controls and 17 patients with isolated hypertriglyceridaemia were matched by age and gender.
RESULTS: Total and active fasting GLP-1 and 2-hour GLP-1 levels were not significantly altered among the 4 groups. However, total and active ΔGLP-1 levels (the difference between 2-hour GLP-1 and fasting GLP-1 levels) were significantly reduced in the isolated HTG, DM, and DM + HTG groups, particularly the DM + HTG group. The ratio of serum active GLP-1 (AGLP-1) to total GLP-1 (TGLP-1) levels was also decreased in patients with isolated HTG, suggesting that active GLP-1 secretion may be more seriously impaired. Both ΔTGLP-1 and ΔAGLP-1 levels were negatively correlated with serum TG levels, body mass index and fasting plasma glucose (FPG) levels and positively correlated with HDL-C levels. According to the multivariate linear regression analysis, only TG and FPG levels were independently associated with ΔTGLP-1 and ΔAGLP-1 levels.
CONCLUSION: Impaired GLP-1 secretion was associated with hypertriglyceridaemia and diabetes, and a more obvious association was noted in hypertriglyceridaemic patients with diabetes.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  diabetes mellitus; glucagon-like peptide 1; hypertriglyceridaemia; lipotoxicity

Mesh:

Substances:

Year:  2017        PMID: 29135069     DOI: 10.1002/dmrr.2964

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  1 in total

1.  The Impact of Incretin-Based Medications on Lipid Metabolism.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-12-29       Impact factor: 4.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.